Histologic disease activity control as a therapeutic target in Crohn ’s disease patients: A word of caution
In recent years, despite the persistence of heterogeneous definitions, mucosal healing has become a relevant goal in the treatment of patients with inflammatory bowel disease (IBD) [1]. In addition, in ulcerative colitis (UC), histological healing has demonstrated a potential prognostic value, overcoming the macroscopic endoscopic exclusive evaluation [2], and allowing that histological improvement could be suggested as a relevant end-point for clinical trials by European and American regulatory agencies.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Cristiano Pagnini, Maria Carla Di Paolo, Marco Giordano, Maria Giovanna Graziani Source Type: research
More News: Clinical Trials | Crohn's Disease | Gastroenterology | Inflammatory Bowel Disease | Liver | Liver Disease | Ulcerative Colitis | Urology & Nephrology